Locoregional Therapies for Hepatocellular Carcinoma: The current Status and Future Perspectives

Overview

Journal United European Gastroenterol J

Publisher Wiley

Specialty Gastroenterology

Date 2024 Feb 19

PMID 38372444

Authors

Jian-Jian Chen

Zhi-Cheng Jin

Bin-Yan Zhong

Wenzhe Fan

Wei-Hua Zhang

Biao Luo

Yu-Qing Wang

Gao-Jun Teng

Hai-Dong Zhu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.

Citing Articles

Diagnostic value of a lactylation-related gene signature in hepatocellular carcinoma.

Zhang J, Dong C, Wu L, Chen L, Zhang L, Shi L Transl Cancer Res. 2025; 14(1):296-312.

PMID: 39974411 PMC: 11833428. DOI: 10.21037/tcr-24-1023.

IGF2BP1 accelerates the aerobic glycolysis to boost its immune escape in hepatocellular carcinoma microenvironment.

Ye X, Lin J, Chen Y, Wang X Front Immunol. 2024; 15:1480834.

PMID: 39606242 PMC: 11599169. DOI: 10.3389/fimmu.2024.1480834.

Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy.

Guo F, Hu H, Peng H, Liu J, Tang C, Zhang H Am J Cancer Res. 2024; 14(9):4580-4596.

PMID: 39417194 PMC: 11477842. DOI: 10.62347/BEAO1926.

Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report.

Liang L, Huang W, Guo Z, You H, Guo Y, Cai M World J Gastroenterol. 2024; 30(36):4071-4077.

PMID: 39351247 PMC: 11439119. DOI: 10.3748/wjg.v30.i36.4071.

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.

Chen J, Jin Z, Zhong B, Fan W, Zhang W, Luo B United European Gastroenterol J. 2024; 12(2):226-239.

PMID: 38372444 PMC: 10954431. DOI: 10.1002/ueg2.12554.

References

Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D . Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022; 174:68-77. DOI: 10.1016/j.ejca.2022.07.005. View

Lencioni R, Llovet J, Han G, Tak W, Yang J, Guglielmi A . Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016; 64(5):1090-1098. DOI: 10.1016/j.jhep.2016.01.012. View

Raoul J, Forner A, Bolondi L, Cheung T, Kloeckner R, De Baere T . Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2018; 72:28-36. DOI: 10.1016/j.ctrv.2018.11.002. View

Llovet J, Real M, Montana X, Planas R, Coll S, Aponte J . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319):1734-9. DOI: 10.1016/S0140-6736(02)08649-X. View

Salem R, Lewandowski R, Mulcahy M, Riaz A, Ryu R, Ibrahim S . Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2009; 138(1):52-64. DOI: 10.1053/j.gastro.2009.09.006. View

Ahmed O, Pillai A . Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020; 115(11):1733-1736. DOI: 10.14309/ajg.0000000000000931. View

Pinato D, Murray S, Forner A, Kaneko T, Fessas P, Toniutto P . Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021; 9(9). PMC: 8487214. DOI: 10.1136/jitc-2021-003311. View

Ricke J, Klumpen H, Amthauer H, Bargellini I, Bartenstein P, De Toni E . Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019; 71(6):1164-1174. DOI: 10.1016/j.jhep.2019.08.006. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

10.

Cao Y, Xiong F, Kan X, Guo X, Ouyang T, Wang R . Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: Three birds with one stone. Pharmacol Res. 2022; 187:106581. DOI: 10.1016/j.phrs.2022.106581. View

11.

Mehta N, Bhangui P, Yao F, Mazzaferro V, Toso C, Akamatsu N . Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020; 104(6):1136-1142. DOI: 10.1097/TP.0000000000003174. View

12.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

13.

Millonig G, Graziadei I, Freund M, Jaschke W, Stadlmann S, Ladurner R . Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007; 13(2):272-9. DOI: 10.1002/lt.21033. View

14.

Zhu H, Li H, Huang M, Yang W, Yin G, Zhong B . Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023; 8(1):58. PMC: 9905571. DOI: 10.1038/s41392-022-01235-0. View

15.

Peng Z, Zhang Y, Liang H, Lin X, Guo R, Chen M . Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2011; 262(2):689-700. DOI: 10.1148/radiol.11110637. View

16.

Hocquelet A, Aube C, Rode A, Cartier V, Sutter O, Manichon A . Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. J Hepatol. 2016; 66(1):67-74. DOI: 10.1016/j.jhep.2016.07.010. View

17.

Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T . A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005; 129(1):122-30. DOI: 10.1053/j.gastro.2005.04.009. View

18.

Wang Z, Liu M, Zhang D, Wu S, Hong Z, He G . Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022; 76(1):66-77. DOI: 10.1002/hep.32323. View

19.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca A, Pageaux G . Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12):1624-1636. DOI: 10.1016/S1470-2045(17)30683-6. View

20.

De Luna W, Sze D, Ahmed A, Ha B, Ayoub W, Keeffe E . Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant. 2009; 9(5):1158-68. DOI: 10.1111/j.1600-6143.2009.02576.x. View